In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.

Date:         Monday June 18, 2018

Time:        14:00 CEST | 13:00 BST | 08:00 EDT

Conference call participants should start calling the number below 10-15 minutes before the conference is due to start.

Dial-in:      CH: +41 (0)44 580 65 22 |  UK: +44 203 009 2470  |  US: +1 877 423 0830

PIN:           66706100#

• Investor webcast
• Investor webcast presentation

In June 2018, Idorsia announced that the first patients had been enrolled in a registration study to investigate the effect of nemorexant (proposed INN for ACT-541468), a dual orexin receptor antagonist, for the treatment of adult and elderly patients with insomnia.

• Investor webcast
• Investor webcast presentation

In May 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.

• Investor webcast
• Investor webcast presentation

Idorsia published its full year financial results 2017 on Tuesday 6 February 2018.

• Investor webcast
• Investor webcast MP3
• Investor webcast presentation

Idorsia offers an electronic ‘Stay Informed’ service where subscribers can automatically receive updates via e-mail or SMS alert.

• Stay informed